FDA Approves FLUOROURACIL — Sagent Pharmaceuticals

# FDA Approves Sagent Pharmaceuticals' Generic Fluorouracil Injection Sagent Pharmaceuticals has received FDA approval for its generic fluorouracil intravenous formulation, expanding the competitive landscape for this widely-used chemotherapy agent and potentially reducing treatment costs for cancer patients. The approval of the generic version is expected to increase price competition in the oncology market and provide healthcare providers with additional sourcing options for this essential chemotherapy drug.